Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 2, 2008, Pages 187-199

  Hunt, R H ^a   Armstrong, D ^a   Yaghoobi, M ^a   James, C ^a   Chen, Y ^a   Leonard, J ^a   Shin, J M ^b   Lee, E ^c   Tang Liu, D ^c   Sachs, G ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGN 201904 Z; ESOMEPRAZOLE; GASTRIN; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ABDOMINAL DISTENSION; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DYSPEPSIA; EPISTAXIS; FLATULENCE; GASTRIN BLOOD LEVEL; HEADACHE; HELICOBACTER PYLORI; HUMAN; HUMAN EXPERIMENT; HUNGER; MALE; MORNING DOSAGE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; STOMACH PH; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN;

ADULT; ANTI-ULCER AGENTS; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; OMEPRAZOLE; PROTON PUMP INHIBITORS; TREATMENT OUTCOME;

EID: 45549091042     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03725.x     Document Type: Article

References (21)

1. Bell NJ, Hunt RH. Progress with proton pump inhibition. Yale J Biol Med 1992 65 : 649 57 discussion 689-92.
2. Jones DB, Howden CW, Burget DW, Kerr GD, Hunt RH. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987 28 : 1120 7.
3. Howden CW, Jones DB, Peace KE, Burget DW, Hunt RH. The treatment of gastric ulcer with antisecretory drugs. Relationship of pharmacological effect to healing rates. Dig Dis Sci 1988 33 : 619 24.
4. Burget DW, Chiverton SG, Hunt RH. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression Gastroenterology 1990 99 : 345 51.
5. Bell NJ, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992 33 : 118 24.
6. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002 97 : 575 83.
7. Richter JE, Kahrilas PJ, Johanson J, et al. Esomeprazole Study Investigators. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001 96 : 656 65.
8. Crawley J, Hamelin B, Gallagher E. How satisfied are chronic heartburn sufferers with the results they get from prescription strength heartburn medication? Gastroenterology 2000 118 : A210.
9. Dean BB, Gano AD Jr., Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004 2 : 656 64.
10. Holzer P. Taste receptors in the gastrointestinal tract. V. Acid sensing in the gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol 2007 292 : G699 705.
11. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998 56 : 307 35.
12. Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006 23 (Suppl. 2 2 8.
13. Lundell L, Miettinen P, Myrvold HE, et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease. J Am Coll Surg 2001 192 : 172 9.
14. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005 22 (Suppl. 3 10 9.
15. Andersson T, Andren K, Cederberg C, Lagerstrom PO, Lundborg P, Skanberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990 29 : 557 63.
16. Hunt RH, Armstrong D, James C, et al. Effect on intragastric pH of a PPI with a prolonged plasma half-life: comparison between tenatoprazole and esomeprazole on the duration of acid suppression in healthy male volunteers. Am J Gastroenterol 2005 100 : 1949 56.
17. +)-ATPase by proton pump inhibitors. J Am Chem Soc 2004 126 : 7800 11.
18. Gardner JD, Rodriguez-Stanley S, Robinson M. Integrated acidity and the pathophysiology of GERD. Am J Gastroenterol 2001 96 : 1363 70.
19. Ouatu-Lascar R, Fitzgerald RC, Triadafilopoulos G. Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 1999 117 : 327 35.
20. Hillman LC, Chiragakis L, Shadbolt B, Kaye GL, Clarke AC. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 2004 180 : 387 91.
21. Allen A, Pearson JP, Blackburn A, Coan RM, Hutton DA, Mall AS. Pepsins and the mucus barrier in peptic ulcer disease. Scand J Gastroenterol Suppl 1988 146 : 50 7.